KROS NASDAQ
Keros Therapeutics, Inc.
1W: -2.2%
1M: +1.2%
3M: +3.0%
YTD: -38.7%
1Y: -25.6%
3Y: -64.5%
5Y: -65.6%
$11.36
+0.10 (+0.89%)
Weekly Expected Move ±4.8%
$10
$11
$11
$12
$12
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
Supply Chain Overview
10 relationships10
As Filer
counterparties named
0
As Counterparty
mentioned by others
3
Rel. Types
2021-09-09
Earliest Filing
2025-10-15
Latest Filing
investor: 6
partner: 3
licensee: 1
Counterparties (Filed by KROS)
10 relationshipsCompanies named in KROS's SEC 8-K filings as business counterparties.
| Counterparty | Ticker | Relationship | Summary | Filing Date | SEC |
|---|---|---|---|---|---|
| ADAR1 Capital Management | — | investor | Entities affiliated with ADAR1 Capital Management entered into a stock purchase agreement to sell shares back to the Com | 2025-10-15 | View |
| Pontifax Venture Capital | — | investor | Entities affiliated with Pontifax Venture Capital entered into a stock purchase agreement to sell shares back to the Com | 2025-10-15 | View |
| Pontifax (Israel) IV, L.P. | — | investor | Investor entered into a letter agreement regarding director nominations and standstill restrictions. | 2025-04-18 | View |
| Pontifax (Cayman) IV, L.P. | — | investor | Investor entered into a letter agreement regarding director nominations and standstill restrictions. | 2025-04-18 | View |
| Pontifax (China) IV, L.P. | — | investor | Investor entered into a letter agreement regarding director nominations and standstill restrictions. | 2025-04-18 | View |
| Pontifax Late Stage Fund L.P. | — | investor | Investor entered into a letter agreement regarding director nominations and standstill restrictions. | 2025-04-18 | View |
| Computershare Trust Company, N.A. | — | partner | Serves as Rights Agent and transfer agent for the Rights Agreement. | 2025-04-10 | View |
| Revolution Labs Owner, LLC | — | partner | Landlord entering into a lease amendment for office and laboratory space. | 2023-01-06 | View |
| Hansoh (Shanghai) Healthtech Co., Ltd. | — | licensee | Exclusive license agreement for development, manufacture, and commercialization of KER-050 in mainland China, Hong Kong, | 2021-12-13 | View |
| Revolution Labs Owner, LLC | — | partner | Lease agreement for office and laboratory space | 2021-09-09 | View |
Recent 8-K Filings (20)
| Filing Date | Description | Type | SEC |
|---|---|---|---|
| 2026-09-29 | Regulation FD; Exhibits | View | |
| 2026-09-28 | Regulation FD; Exhibits | View | |
| 2026-09-08 | Other Events; Exhibits | View | |
| 2026-08-03 | Earnings Release; Exhibits | View | |
| 2026-08-03 | Regulation FD; Exhibits | View | |
| 2026-07-30 | Regulation FD; Exhibits | View | |
| 2026-07-22 | Officer/Director Change | View | |
| 2026-06-25 | Officer/Director Change; Regulation FD; Exhibits | View | |
| 2026-06-03 | Shareholder Vote | View | |
| 2026-06-01 | Regulation FD; Exhibits | View | |
| 2026-05-14 | Earnings Release; Exhibits | View | |
| 2026-03-09 | Other Events; Financial Statements and Exhibits | View | |
| 2026-03-04 | Results of Operations and Financial Condition; Financial Statements and Exhibits | View | |
| 2026-03-04 | Regulation FD Disclosure; Financial Statements and Exhibits | View | |
| 2026-02-26 | Departure/Election of Directors; Appointment of Officers; Regulation FD Disclosure; Financial Statem | View | |
| 2026-02-18 | Regulation FD Disclosure; Financial Statements and Exhibits | View | |
| 2026-01-09 | Regulation FD Disclosure; Financial Statements and Exhibits | View | |
| 2025-11-05 | Results of Operations and Financial Condition; Financial Statements and Exhibits | View | |
| 2025-10-15 | Entry into Material Definitive Agreement; Results of Operations and Financial Condition; Departure/E | Agreement | View |
| 2025-09-08 | Other Events; Financial Statements and Exhibits | View |
Data extracted from SEC EDGAR 8-K filings using NLP. Relationships are as disclosed in filing text.
Covers 2021–2026. View on SEC EDGAR